专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06833237B1 Genes involved in stroke response and/or regulated by FK506, proteins encoded thereby, and methods of use 失效
标题翻译：涉及卒中反应和/或由FK506调节的基因，由此编码的蛋白质和使用方法
公开(公告)号：US06833237B1
公开(公告)日：2004-12-21
申请号：US10021338
申请日：2001-12-12
申请人： Elena Feinstein , Igor Mett , Sylvia G. Kachalsky , Svetlana Gorodin
发明人： Elena Feinstein , Igor Mett , Sylvia G. Kachalsky , Svetlana Gorodin
IPC分类号： C12Q100
CPC分类号： C07K14/705 , G01N2500/00
摘要： Genes and the proteins encoded thereby that are involved in stroke response and/or are regulated by FK506 are disclosed. These genes were discovered using in vivo or in vitro stroke models by determining which genes were differentially upregulated or downregulated upon treatment of the model with FK506. They were also found by a functional assay of genes specifically selected for conferring to cells resistance to hypoxia, dopamine or glutamate treatment. The disclosure includes such genes and proteins as well as analogs, salts and functional derivatives of such proteins, and DNA encoding such analogs, and methods of use. Methods for treating the effects of stroke, hypoxia and/or ischemia by regulating such genes or proteins are disclosed. Methods for screening for compounds capable of regulating the genes and proteins of the invention are also disclosed.
摘要翻译：公开了基因和由其编码的涉及中风反应和/或由FK506调节的蛋白质。使用体内或体外卒中模型，通过确定哪些基因在用FK506处理模型时差异上调或下调，发现这些基因。它们也通过功能性测定法发现，其特异性选择用于赋予细胞对缺氧，多巴胺或谷氨酸处理的抗性。本公开包括此类基因和蛋白质以及此类蛋白质的类似物，盐和功能性衍生物，以及编码此类类似物的DNA及其使用方法。公开了通过调节这些基因或蛋白质来治疗中风，缺氧和/或缺血的作用的方法。还公开了能够调节本发明的基因和蛋白质的化合物的筛选方法。

2. 发明申请

US20080249038A1 Bone Morphogenetic Protein (Bmp) 2A and Uses Thereof 审中-公开
标题翻译：骨形态发生蛋白（Bmp）2A及其用途
公开(公告)号：US20080249038A1
公开(公告)日：2008-10-09
申请号：US10575121
申请日：2004-10-06
申请人： Elena Feinstein , Igor Mett , Svetlana Gorodin , Michael Shtutman
发明人： Elena Feinstein , Igor Mett , Svetlana Gorodin , Michael Shtutman
IPC分类号： A61K31/7088 , C07H21/04 , C12N15/00
CPC分类号： C12N15/1136 , C12N2310/11 , C12N2310/111 , C12N2310/14
摘要： The present invention provides compositions and methods for alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues whether resulting from tissue trauma, or from chronic or acute degenerative changes. In particular, some embodiments of the present invention provide one or more pharmaceutical compositions comprising as an active ingredient a BMP2A inhibitor further comprising a pharmaceutically acceptable diluent or carrier. An additional embodiment provides a method for reducing damage to the central nervous system in a patient who has suffered an injury to the central nervous system, comprising administering to the patient a pharmaceutical composition in a dosage sufficient to reduce the damage. Yet another embodiment provides of the use of a BMP2A inhibitor for the preparation of a medicament for promoting or enhancing recovery in a patient who has suffered an injury to the central nervous system. Preferable inhibitors according to some embodiments of the invention are siRNA molecules and neutralizing antibodies. An additional embodiment provides a method for identifying a chemical compound that modulates apoptosis. Further, a process for diagnosing a neurodegenerative disease or an ischemic event in a subject is provided. The preferred methods, materials, and examples that will now be described are illustrative only and are not intended to be limiting; materials and methods similar or equivalent to those described herein can be used in practice or testing of the invention. Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
摘要翻译：本发明提供用于缓解或减少与损伤的神经元组织相关的症状和体征的组合物和方法，无论是由组织创伤引起的，还是由慢性或急性退行性变化引起。特别地，本发明的一些实施方案提供一种或多种药物组合物，其包含作为活性成分的进一步包含药学上可接受的稀释剂或载体的BMP2A抑制剂。另一个实施方案提供了减轻对中枢神经系统损伤的患者中的中枢神经系统的损伤的方法，包括以足以减少损伤的剂量向患者施用药物组合物。另一个实施方案提供了BMP2A抑制剂用于制备用于促进或增强患有中枢神经系统损伤的患者的恢复的药物的用途。根据本发明一些实施方案的优选的抑制剂是siRNA分子和中和抗体。另外的实施方案提供了鉴定调节细胞凋亡的化合物的方法。此外，提供了用于诊断受试者中的神经变性疾病或缺血事件的方法。现在将要描述的优选方法，材料和实施例仅是说明性的而不是限制性的; 可以在本发明的实践或测试中使用与本文所述类似或等同的材料和方法。从以下详细描述和权利要求书中，本发明的其它特征和优点将变得显而易见。

3. 发明申请

US20160333354A1 DOUBLE STRANDED RNA COMPOUNDS TO RHOA AND USE THEREOF 审中-公开
公开(公告)号：US20160333354A1
公开(公告)日：2016-11-17
申请号：US15228214
申请日：2016-08-04
申请人： Sharon Avkin-Nachum , Elena Feinstein , Hagar Kalinski , Igor Mett
发明人： Sharon Avkin-Nachum , Elena Feinstein , Hagar Kalinski , Igor Mett
IPC分类号： C12N15/113 , C12Q1/68
CPC分类号： C12N15/1135 , C12N15/1137 , C12N2310/14 , C12N2310/141 , C12N2310/321 , C12Q1/6888
摘要： The present invention relates to compounds, pharmaceutical compositions comprising same, methods of use thereof and kits for the down-regulation of RhoA gene. The compounds, compositions, methods and kits are useful in the treatment of subjects suffering from diseases or conditions and or symptoms associated with diseases or conditions in which RhoA expression has adverse consequences and for conferring neuroprotection.

4. 发明申请

US20160102313A1 DOUBLE STRANDED RNA COMPOUNDS TO RHOA AND USE THEREOF 审中-公开
公开(公告)号：US20160102313A1
公开(公告)日：2016-04-14
申请号：US14973388
申请日：2015-12-17
申请人： Sharon Avkin-Nachum , Elena Feinstein , Hagar Kalinski , Igor Mett
发明人： Sharon Avkin-Nachum , Elena Feinstein , Hagar Kalinski , Igor Mett
IPC分类号： C12N15/113
CPC分类号： C12N15/1135 , C12N15/1137 , C12N2310/14 , C12N2310/141 , C12N2310/321 , C12Q1/6888
摘要： The present invention relates to compounds, pharmaceutical compositions comprising same, methods of use thereof and kits for the down-regulation of RhoA gene. The compounds, compositions, methods and kits are useful in the treatment of subjects suffering from diseases or conditions and or symptoms associated with diseases or conditions in which RhoA expression has adverse consequences and for conferring neuroprotection.

5. 发明申请

US20140350068A1 RTP801L SIRNA COMPOUNDS AND METHODS OF USE THEREOF 审中-公开
标题翻译： RTP801L SIRNA化合物及其使用方法
公开(公告)号：US20140350068A1
公开(公告)日：2014-11-27
申请号：US14139584
申请日：2013-12-23
申请人： Elena Feinstein , Igor Mett , Hagar Kalinski
发明人： Elena Feinstein , Igor Mett , Hagar Kalinski
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , C07H21/02 , C12N2310/14 , C12N2310/319 , C12N2310/343 , C12N2310/321 , C12N2310/3521
摘要： The invention provides chemically modified siRNA oligonucleotides that target RTP801L, compositions comprising same and to the use of such molecules to treat, inter alia, respiratory diseases including acute and chronic pulmonary disorders, eye diseases including glaucoma and ION, microvascular disorders, angiogenesis- and apoptosis-related conditions, and hearing impairments.
摘要翻译：本发明提供靶向RTP801L的化学修饰的siRNA寡核苷酸，包含其的组合物，以及使用此类分子治疗尤其是呼吸系统疾病，包括急性和慢性肺病，包括青光眼和ION在内的眼睛疾病，微血管病症，血管生成和凋亡相关条件和听力障碍。

6. 发明授权

US08614309B2 Double-stranded RNA directed to CASP2 and methods of use thereof 有权
标题翻译：针对CASP2的双链RNA及其使用方法
公开(公告)号：US08614309B2
公开(公告)日：2013-12-24
申请号：US12733998
申请日：2008-09-04
申请人： Elena Feinstein , Huseyin Aygun , Rami Skaliter , Hagar Kalinski , Igor Mett , James McSwiggen , Leonid Beigelman
发明人： Elena Feinstein , Huseyin Aygun , Rami Skaliter , Hagar Kalinski , Igor Mett , James McSwiggen , Leonid Beigelman
IPC分类号： C07H21/04
CPC分类号： C07H21/02 , C12N15/111 , C12N2310/14 , C12N2310/319 , C12N2310/321 , C12N2310/3231 , C12N2310/332 , C12N2310/346 , C12N2320/51 , C12N2310/3521
摘要： The invention relates to siRNA compounds possessing novel sequences and structural motifs which down-regulate the expression of specific human genes. The invention also relates to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The present invention also provides a method of treating and/or preventing the incidence or severity of various diseases or conditions associated with the genes and/or symptoms associated with such diseases or conditions comprising administering to a subject in need of treatment for such disease or condition and/or symptom the compound or the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the subject.
摘要翻译：本发明涉及具有下调特定人基因表达的新型序列和结构基序的siRNA化合物。本发明还涉及包含这些化合物和药学上可接受的载体的药物组合物。本发明还提供了治疗和/或预防与这些疾病或病症相关的基因和/或症状相关的各种疾病或病症的发生率或严重程度的方法，包括向需要治疗的受试者施用此类疾病或病症和/或治疗有效剂量的化合物或药物组合物的症状，从而治疗受试者。

7. 发明申请

US20080064650A1 Therapeutic uses of inhibitors of RTP801L 有权
标题翻译： RTP801L抑制剂的治疗用途
公开(公告)号：US20080064650A1
公开(公告)日：2008-03-13
申请号：US11811112
申请日：2007-06-08
申请人： Elena Feinstein , Igor Mett
发明人： Elena Feinstein , Igor Mett
IPC分类号： A61K31/712 , A61P11/00 , A61P11/06 , A61P25/00 , A61P27/00 , A61P27/06 , A61P9/00 , C07H21/02
CPC分类号： C12N15/113 , C12N2310/14 , C12N2310/321 , C12N2320/31 , C12N2310/3521
摘要： The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases respiratory conditions and hearing disorders based upon inhibition of the RTP801L gene and/or protein.
摘要翻译：本发明提供了基于RTP801L基因和/或蛋白质的抑制来治疗微血管病症，眼睛疾病呼吸系统疾病和听力障碍的新型分子，组合物，方法和用途。

8. 发明授权

US09045755B2 Double stranded RNA compounds to RhoA and use thereof 有权
标题翻译： RhoA的双链RNA化合物及其用途
公开(公告)号：US09045755B2
公开(公告)日：2015-06-02
申请号：US13700942
申请日：2011-06-23
申请人： Sharon Avkin-Nachum , Elena Feinstein , Hagar Kalinski , Igor Mett
发明人： Sharon Avkin-Nachum , Elena Feinstein , Hagar Kalinski , Igor Mett
IPC分类号： C07H21/04 , C12N15/113
CPC分类号： C12N15/1135 , C12N15/1137 , C12N2310/14 , C12N2310/141 , C12N2310/321 , C12Q1/6888
摘要： The present invention relates to compounds, pharmaceutical compositions comprising same, methods of use thereof and kits for the down-regulation of RhoA gene. The compounds, compositions, methods and kits are useful in the treatment of subjects suffering from diseases or conditions and or symptoms associated with diseases or conditions in which RhoA expression has adverse consequences and for conferring neuroprotection.
摘要翻译：本发明涉及化合物，包含其的药物组合物，其使用方法和用于下调RhoA基因的试剂盒。化合物，组合物，方法和试剂盒可用于治疗患有RhoA表达具有不良后果和赋予神经保护作用的疾病或病症和/或与疾病或病症相关的症状的受试者。

9. 发明申请

US20150018404A1 DOUBLE-STRANDED OLIGONUCLEOTIDE COMPOUNDS FOR TREATING HEARING AND BALANCE DISORDERS 审中-公开
标题翻译：用于治疗听觉和平衡障碍的双链寡核苷酸化合物
公开(公告)号：US20150018404A1
公开(公告)日：2015-01-15
申请号：US14235780
申请日：2012-08-03
申请人： Elena Feinstein , Sharon Avkin-Nachum , Igor Mett , Hagar Kalinski
发明人： Elena Feinstein , Sharon Avkin-Nachum , Igor Mett , Hagar Kalinski
IPC分类号： C12N15/113
CPC分类号： C12N15/113 , C12N2310/11 , C12N2310/14 , C12N2310/321 , C12N2310/332 , C12N2310/333 , C12N2310/3341 , C12N2310/335 , C12N2310/336 , C12N2310/337 , C12N2310/3521 , C12N2310/50
摘要： The present application relates to double stranded nucleic acid compounds, compositions comprising same and methods of use thereof for the treatment of hearing loss in a subject in need thereof. The compounds are preferably chemically synthesized and modified dsRNA molecules which inhibit expression of a gene expressed selected from the group consisting of HES1, HES5, HEY1, HEY2, ID1, ID2, ID3, CDKN1B, and NOTCH1.
摘要翻译：本申请涉及双链核酸化合物，包含其的组合物以及用于治疗有此需要的受试者的听力损失的方法。所述化合物优选化学合成并抑制表达选自HES1，HES5，HEY1，HEY2，ID1，ID2，ID3，CDKN1B和NOTCH1的基因表达的dsRNA分子。

10. 发明申请

US20140005253A1 COMPOSITIONS AND METHODS FOR TREATING LUNG DISEASE AND INJURY 有权
标题翻译：用于治疗肺部疾病和伤害的组合物和方法
公开(公告)号：US20140005253A1
公开(公告)日：2014-01-02
申请号：US14002660
申请日：2012-03-01
申请人： Andrew E. Gelman , Elena Feinstein , Svetlana Adamsky , Igor Mett , Hagar Kalinski , Sharon Avkin-Nachum
发明人： Andrew E. Gelman , Elena Feinstein , Svetlana Adamsky , Igor Mett , Hagar Kalinski , Sharon Avkin-Nachum
IPC分类号： A61K31/713
CPC分类号： C12N15/113 , A61K31/713 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2310/321 , C12N2310/344 , C12N2310/3521
摘要： Disclosed herein are therapeutic methods for treating lung diseases, disorders and injury in a mammal, including treatment of acute respiratory distress syndrome (ARDS), acute lung injury, pulmonary fibrosis (idiopathic), bleomycin induced pulmonary fibrosis, mechanical ventilator induced lung injury, chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, bronchiolitis obliterans after lung transplantation and lung transplantation-induced acute graft dysfunction, including treatment, prevention or prevention of progression of primary graft failure, ischemia-reperfusion injury, reperfusion injury, reperfusion edema, allograft dysfunction, pulmonary reimplantation response, bronchiolitis obliterans after lung transplantation and/or primary graft dysfunction (PGD) after organ transplantation, in particular in lung transplantation, comprising downregulating the TLR2 gene or both the TLR2 gene and TLR4 gene. Provided herein are compositions, methods and kits for treating lung diseases, disorders and injury.
摘要翻译：本文公开了治疗哺乳动物肺疾病，病症和损伤的治疗方法，包括治疗急性呼吸窘迫综合征（ARDS），急性肺损伤，肺纤维化（特发性），博来霉素诱导的肺纤维化，机械通气机诱导的肺损伤，慢性阻塞性肺疾病（COPD），慢性支气管炎，肺气肿，肺移植后闭塞性细支气管炎和肺移植引起的急性移植物功能障碍，包括治疗，预防或预防原发性移植物衰竭，缺血再灌注损伤，再灌注损伤，再灌注水肿，同种异体移植功能障碍，肺再植入反应，肺移植后闭塞性细支气管炎和/或器官移植后特别是肺移植中的原发性移植物功能障碍（PGD），包括下调TLR2基因或TLR2基因和TLR4基因。本文提供了用于治疗肺部疾病，病症和损伤的组合物，方法和试剂盒。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式